Tangent Reprofiling. Development of prototype: TAN2004, a safe, known drug formulated for treatment of prostate and lung cancer.

切线重新轮廓分析。

• 批准号: 720370
• 金额: $ 27.41万
• 依托单位: VALISEEK LIMITED
• 依托单位国家: 英国
• 项目类别: GRD Development of Prototype
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=720370
• 关键词: Tangent; Reprofiling.; Development; prototype; TAN2004

Some cancerous tumors require, or grow faster in the presence of, steroid hormones such asestrogen or testosterone. These cancers can be treated by chemotherapy drugs to prevent thetumor using hormones found naturally in the body. Many of these drugs work by blocking thereceptors for the hormone on the outside edges of the tumor, starving the tumor by preventingit from recognizing the hormone. However, many hormone-dependant tumors developresistance to these drugs by learning to make the hormones internally.We used our proprietary technology to study drugs that are currently used in non-cancerdiseases. One drug was identified as being capable of preventing internal hormone productionby tumors. This drug is already in clinical use for an alternative disease which requires longterm use, so the safety and side effects are already well characterized across a broadpopulation of patients. We propose combining this drug with a common, safe nutritionalsupplement to attack the tumor from within while maintaining the starvation proceduredescribed above.We already have data to demonstrate a reduction in growth of prostate cancer cells with thedrug in vitro, and preliminary efficacy data for prostate tumors in mice, however, we nowneed to expand this to optimise the prototype drug combination formulation and dosingschedule. We also look to expand the use into lung cancer, for which we have already seenpromising in vitro data. This project includes a first in vivo lung cancer model as well asadvanced stage prostate cancer mouse models.This project period will develop our prototype cancer treatment from proof of concept toclinic-ready, ensuring partnering for clinical development is likely on conclusion.We believe this offers an exciting opportunity to prolong successful treatment of a range ofcommon cancers including prostate and lung cancer.

一些癌性肿瘤需要类固醇激素如雌激素或睾酮，或者在类固醇激素存在的情况下生长得更快。这些癌症可以通过化疗药物来治疗，以防止肿瘤使用激素在体内自然发现。这些药物中有许多是通过阻断肿瘤外边缘的激素受体来起作用的，通过阻止肿瘤识别激素来使肿瘤饥饿。然而，许多依赖激素的肿瘤通过学习在体内制造激素而对这些药物产生耐药性。我们使用我们的专有技术来研究目前用于非癌症疾病的药物。有一种药物被鉴定为能够阻止肿瘤产生内部激素。这种药物已经在临床上用于需要长期使用的替代疾病，因此安全性和副作用已经在广泛的患者人群中得到了很好的表征。我们建议将这种药物与一种常见的、安全的营养补充剂结合起来，从内部攻击肿瘤，同时保持上述的饥饿过程。我们已经有数据证明这种药物在体外可以减少前列腺癌细胞的生长，以及对小鼠前列腺肿瘤的初步疗效数据，然而，我们现在需要扩大这一点，以优化原型药物组合配方和给药时间表。我们还希望将其用于肺癌，我们已经看到了有希望的体外数据。该项目包括第一个体内肺癌模型以及晚期前列腺癌小鼠模型。该项目期间将开发我们的原型癌症治疗，从概念验证到临床就绪，确保临床开发的合作可能会结束。我们相信这为延长包括前列腺癌和肺癌在内的一系列常见癌症的成功治疗提供了令人兴奋的机会。